By staff writers

February 24, 2012 -- Ultrasound contrast developer Acusphere has secured $2.5 million in new debt financing.

The company currently is conducting a special protocol assessment with the U.S. Food and Drug Administration (FDA) for a phase III study of its Imagify ultrasound contrast agent.

The study will compare stress ultrasound with Imagify to unenhanced stress ultrasound for detecting coronary artery disease.

If you like this content, please share it with a colleague!
Copyright © 2012

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Sign in using your social networking account:
Sign in using your social networking